-
Parexel Opens Clinical Study Supply Chain Center in Suzhou
•
US-based contract research organization (CRO) Parexel has announced the opening of its clinical study supply chain operation center in Suzhou, Jiangsu Province, China. This new facility will provide critical and ancillary supplies and laboratory logistics services for clinical trials in the Asia Pacific region. Global Network and ServicesThe Suzhou center…
-
Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has been dosed in a Phase I clinical study (ABSK043-101) for its in-house developed oral programmed-death ligand 1 (PD-L1) inhibitor, ABSK043, in patients with advanced solid tumors in China. The drug has previously completed multiple dose…
-
Arctic Vision Enrolls First Patient in Phase III Study for ARVN002
•
China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a Phase III clinical study assessing the efficacy and safety of ARVN002 (atropine sulfate) for arresting myopia progression. The study is being conducted in China and marks a significant step forward in the development of this…
-
3D Medicines Partners with Denfo Medical for Cancer Therapy Development
•
China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group, focusing on the research and development (R&D) and commercialization of novel cancer therapies. The collaboration will also cover cancer chroniclization management and novel drug services. Denfo Medical will leverage its interconnected, digitalized, and intelligent online…
-
Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278
•
China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with Spain-based Almirall S.A. (BME: ALM), granting Almirall exclusive development and commercialization rights to the autoimmune disease drug candidate SIM0278 outside of Greater China. Under the terms of the deal, Almirall will pay Simcere an upfront…
-
Insight Lifetech Raises Funds for Cardiovascular Solutions Expansion
•
Insight Lifetech Co., Ltd, a Shenzhen-based provider of cardiovascular precision intervention solutions, has reportedly secured an undisclosed amount of funding in a Series D+ financing round. The round was led by existing investor Sherpa Healthcare Partners, with additional contributions from Taiping Fund Management, Triwise Capital, and Far East Horizon, as…
-
Santen Pharmaceutical Launches New Plant Construction in Suzhou
•
Japan-based Santen Pharmaceutical Co. has launched the construction of a new plant in Suzhou, Jiangsu Province, China. The 126,000 square meter site is designed to enhance local production capacity for prescription eye drops, anticipating increased demand from the globally aging population. The facility is expected to begin operations in 2025.…
-
Legend Biotech’s Carvykti Approved in Japan for Relapsed Multiple Myeloma
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Carvykti (ciltacabtagene autoleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adults with relapsed or refractory multiple myeloma. The approval is limited to…
